Recent News

• 12.09.2025 - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
• 11.10.2025 - Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.10.2025 - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
• 11.07.2025 - Celldex to Present at Upcoming Investor Conferences
• 11.06.2025 - Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
• 11.06.2025 - Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
• 10.30.2025 - Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
• 09.17.2025 - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Recent Filings

• 12.04.2025 - 144 Report of proposed sale of securities
• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 144 Report of proposed sale of securities
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 3 Initial statement of beneficial ownership of securities
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - 8-K Current report